Research ExplorerPublications2-18fluoro-deoxy-D-glucose positron emission tomography is a...

2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma

Standard

2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma : an update of the prospective multicentric SEMPET trial. / De Santis, Maria; Becherer, Alexander; Bokemeyer, Carsten; Stoiber, Franz; Oechsle, Karin; Sellner, Franz; Lang, Alois; Kletter, Kurt; Dohmen, Bernhard M; Dittrich, Christian; Pont, Jörg.

In: J CLIN ONCOL, Vol. 22, No. 6, 15.03.2004, p. 1034-9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

De Santis, M, Becherer, A, Bokemeyer, C, Stoiber, F, Oechsle, K, Sellner, F, Lang, A, Kletter, K, Dohmen, BM, Dittrich, C & Pont, J 2004, '2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial', J CLIN ONCOL, vol. 22, no. 6, pp. 1034-9. https://doi.org/10.1200/JCO.2004.07.188

APA

De Santis, M., Becherer, A., Bokemeyer, C., Stoiber, F., Oechsle, K., Sellner, F., Lang, A., Kletter, K., Dohmen, B. M., Dittrich, C., & Pont, J. (2004). 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J CLIN ONCOL, 22(6), 1034-9. https://doi.org/10.1200/JCO.2004.07.188

Vancouver

De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J CLIN ONCOL. 2004 Mar 15;22(6):1034-9. https://doi.org/10.1200/JCO.2004.07.188

Bibtex

@article{1ff37b4d026c45db961581260cbb7744,
title = "2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial",
abstract = "PURPOSE: To define the clinical value of 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG PET) as a predictor for viable residual tumor in postchemotherapy seminoma residuals in a prospective multicentric trial.PATIENTS AND METHODS: FDG PET studies in patients with metastatic pure seminoma who had radiographically defined postchemotherapy residual masses were correlated with either the histology of the resected lesion or the clinical outcome documented by computer tomography (CT), tumor markers, and/or physical examination during follow-up. The size of the residual lesions on CT, either >3 cm or < or =3 cm, was correlated with the presence or absence of viable residual tumor.RESULTS: Fifty-six FDG PET scans of 51 patients were assessable. All 19 cases with residual lesions >3 cm and 35 (95%) of 37 with residual lesions < or =3 cm were correctly predicted by FDG PET. The specificity, sensitivity, positive predictive value, and negative predictive value of FDG PET were 100% (95% CI, 92% to 100%), 80% (95% CI, 44% to 95%), 100%, and 96%, respectively, versus 74% (95% CI, 58% to 85%), 70% (95% CI, 34% to 90%), 37%, and 92%, respectively, for CT discrimination of the residual tumor by size (>3 cm/< or =3 cm).CONCLUSION: This investigation confirms that FDG PET is the best predictor of viable residual tumor in postchemotherapy seminoma residuals and should be used as a standard tool for clinical decision making in this patient group.",
keywords = "Austria, Clinical Trials as Topic, Fluorodeoxyglucose F18, Follow-Up Studies, Germany, Humans, Male, Neoplasm, Residual, Predictive Value of Tests, Prospective Studies, Radiopharmaceuticals, Seminoma, Sensitivity and Specificity, Testicular Neoplasms, Tomography, Emission-Computed",
author = "{De Santis}, Maria and Alexander Becherer and Carsten Bokemeyer and Franz Stoiber and Karin Oechsle and Franz Sellner and Alois Lang and Kurt Kletter and Dohmen, {Bernhard M} and Christian Dittrich and J{\"o}rg Pont",
year = "2004",
month = mar,
day = "15",
doi = "10.1200/JCO.2004.07.188",
language = "English",
volume = "22",
pages = "1034--9",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

RIS

TY - JOUR

T1 - 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma

T2 - an update of the prospective multicentric SEMPET trial

AU - De Santis, Maria

AU - Becherer, Alexander

AU - Bokemeyer, Carsten

AU - Stoiber, Franz

AU - Oechsle, Karin

AU - Sellner, Franz

AU - Lang, Alois

AU - Kletter, Kurt

AU - Dohmen, Bernhard M

AU - Dittrich, Christian

AU - Pont, Jörg

PY - 2004/3/15

Y1 - 2004/3/15

N2 - PURPOSE: To define the clinical value of 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG PET) as a predictor for viable residual tumor in postchemotherapy seminoma residuals in a prospective multicentric trial.PATIENTS AND METHODS: FDG PET studies in patients with metastatic pure seminoma who had radiographically defined postchemotherapy residual masses were correlated with either the histology of the resected lesion or the clinical outcome documented by computer tomography (CT), tumor markers, and/or physical examination during follow-up. The size of the residual lesions on CT, either >3 cm or < or =3 cm, was correlated with the presence or absence of viable residual tumor.RESULTS: Fifty-six FDG PET scans of 51 patients were assessable. All 19 cases with residual lesions >3 cm and 35 (95%) of 37 with residual lesions < or =3 cm were correctly predicted by FDG PET. The specificity, sensitivity, positive predictive value, and negative predictive value of FDG PET were 100% (95% CI, 92% to 100%), 80% (95% CI, 44% to 95%), 100%, and 96%, respectively, versus 74% (95% CI, 58% to 85%), 70% (95% CI, 34% to 90%), 37%, and 92%, respectively, for CT discrimination of the residual tumor by size (>3 cm/< or =3 cm).CONCLUSION: This investigation confirms that FDG PET is the best predictor of viable residual tumor in postchemotherapy seminoma residuals and should be used as a standard tool for clinical decision making in this patient group.

AB - PURPOSE: To define the clinical value of 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG PET) as a predictor for viable residual tumor in postchemotherapy seminoma residuals in a prospective multicentric trial.PATIENTS AND METHODS: FDG PET studies in patients with metastatic pure seminoma who had radiographically defined postchemotherapy residual masses were correlated with either the histology of the resected lesion or the clinical outcome documented by computer tomography (CT), tumor markers, and/or physical examination during follow-up. The size of the residual lesions on CT, either >3 cm or < or =3 cm, was correlated with the presence or absence of viable residual tumor.RESULTS: Fifty-six FDG PET scans of 51 patients were assessable. All 19 cases with residual lesions >3 cm and 35 (95%) of 37 with residual lesions < or =3 cm were correctly predicted by FDG PET. The specificity, sensitivity, positive predictive value, and negative predictive value of FDG PET were 100% (95% CI, 92% to 100%), 80% (95% CI, 44% to 95%), 100%, and 96%, respectively, versus 74% (95% CI, 58% to 85%), 70% (95% CI, 34% to 90%), 37%, and 92%, respectively, for CT discrimination of the residual tumor by size (>3 cm/< or =3 cm).CONCLUSION: This investigation confirms that FDG PET is the best predictor of viable residual tumor in postchemotherapy seminoma residuals and should be used as a standard tool for clinical decision making in this patient group.

KW - Austria

KW - Clinical Trials as Topic

KW - Fluorodeoxyglucose F18

KW - Follow-Up Studies

KW - Germany

KW - Humans

KW - Male

KW - Neoplasm, Residual

KW - Predictive Value of Tests

KW - Prospective Studies

KW - Radiopharmaceuticals

KW - Seminoma

KW - Sensitivity and Specificity

KW - Testicular Neoplasms

KW - Tomography, Emission-Computed

U2 - 10.1200/JCO.2004.07.188

DO - 10.1200/JCO.2004.07.188

M3 - SCORING: Journal article

C2 - 15020605

VL - 22

SP - 1034

EP - 1039

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 6

ER -